🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06102161
Starting soon Phase 3

Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)

NCT06102161 · tracked via the Priya Life Science China tracker
Sponsor
Fudan University
Phase
Phase 3
Started
2023-11
Last updated
2023-10-26

Condition(s) studied

Lung CancerWedge ResectionGround-glass Opacity

Investigational drug(s) / intervention(s)

Wedge resection

Wedge resection: Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.

Study summary

This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients who sign the informed consent form and are willing to complete the study according to the plan; 2. Aged from 18 to 80 years old; 3. ECOG equals 0 or 1; 4. Not receiving lung cancer surgery before; 5. Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma; 6. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules; 7. The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm; 8. peripheral type of nodes, namely, nodes in the outer 1/3 of the lung field. 9. cT1N0M0 tumors; 10. Complete tumor resection by wedge resection as assessed by the surgeon; 11. Not receiving chemotherapy or radiotherapy before. Exclusion Criteria: 1. Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma. 2. CTR is not between 0.25-0.5 or nodule size greater than 2 cm; 3. Cannot be completely resected by wedge resection; 4. Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically; 5. Receiving lung cancer surgery before; 6. Receiving radiotherapy or chemotherapy.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fudan University Shanghai Cancer Center Shanghai China

More Fudan University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06102161 on ClinicalTrials.gov ↗ ← All trials in China